Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ACIU NASDAQ:ALT NASDAQ:CNTB NASDAQ:IMAB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$3.59+1.4%$2.42$1.43▼$3.99$355.45M1.56238,789 shs580,941 shsALTAltimmune$3.93-2.0%$3.70$2.90▼$11.16$353.91M0.072.63 million shs1.87 million shsCNTBConnect Biopharma$1.78+11.3%$1.81$0.51▼$2.86$89.15M-0.1587,753 shs196,414 shsIMABI-Mab$4.37+0.5%$4.00$0.60▼$5.90$355.22M1.451.68 million shs1.11 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune-11.28%+16.45%+55.26%+71.01%+4.73%ALTAltimmune+2.56%+5.80%+6.08%-12.45%-35.63%CNTBConnect Biopharma+7.38%+21.48%-8.57%+40.98%+13.48%IMABI-Mab+0.69%+27.19%-0.68%+97.73%+212.95%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeACIUAC Immune$3.59+1.4%$2.42$1.43▼$3.99$355.45M1.56238,789 shs580,941 shsALTAltimmune$3.93-2.0%$3.70$2.90▼$11.16$353.91M0.072.63 million shs1.87 million shsCNTBConnect Biopharma$1.78+11.3%$1.81$0.51▼$2.86$89.15M-0.1587,753 shs196,414 shsIMABI-Mab$4.37+0.5%$4.00$0.60▼$5.90$355.22M1.451.68 million shs1.11 million shsReduce the RiskMarket downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceACIUAC Immune-11.28%+16.45%+55.26%+71.01%+4.73%ALTAltimmune+2.56%+5.80%+6.08%-12.45%-35.63%CNTBConnect Biopharma+7.38%+21.48%-8.57%+40.98%+13.48%IMABI-Mab+0.69%+27.19%-0.68%+97.73%+212.95%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceACIUAC Immune 2.25Hold$10.00178.55% UpsideALTAltimmune 2.38Hold$17.40342.75% UpsideCNTBConnect Biopharma 2.67Moderate Buy$7.00293.26% UpsideIMABI-Mab 2.86Moderate Buy$7.3367.81% UpsideCurrent Analyst Ratings BreakdownLatest CNTB, ACIU, IMAB, and ALT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/3/2025IMABI-MabLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$9.0010/3/2025IMABI-MabLeerink PartnrsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy9/27/2025ACIUAC ImmuneWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025ALTAltimmuneWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CNTBConnect BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025IMABI-MabWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/10/2025IMABI-MabNew Street ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$7.009/9/2025ACIUAC ImmuneZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold9/9/2025IMABI-MabBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$7.009/8/2025ACIUAC ImmuneBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$8.009/8/2025IMABI-MabNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$6.00(Data available from 10/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookACIUAC Immune$31.02M11.62N/AN/A$1.29 per share2.78ALTAltimmune$20K17,343.09N/AN/A$1.74 per share2.26CNTBConnect Biopharma$26.03M3.81N/AN/A$1.67 per share1.07IMABI-Mab$3.89M91.74N/AN/A$2.47 per share1.77Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateACIUAC Immune-$57.83M-$0.58N/AN/AN/A-174.94%-49.35%-23.16%11/4/2025 (Estimated)ALTAltimmune-$95.06M-$1.18N/AN/AN/A-438,730.03%-62.63%-55.29%11/11/2025 (Estimated)CNTBConnect Biopharma-$15.63MN/A0.00N/AN/AN/AN/AN/AN/AIMABI-Mab-$22.23MN/A0.00N/AN/AN/A-19.65%-18.58%11/13/2025 (Estimated)Latest CNTB, ACIU, IMAB, and ALT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/4/2025Q3 2025ACIUAC Immune-$0.23N/AN/AN/A$0.81 millionN/A8/20/2025Q2 2025IMABI-Mab-$0.10-$0.07+$0.03-$0.07N/AN/A8/12/2025Q2 2025ALTAltimmune-$0.32-$0.27+$0.05-$0.27$0.00 million$0.01 million8/5/2025Q2 2025ACIUAC Immune-$0.20-$0.25-$0.05-$0.25$1.98 million$1.65 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthACIUAC ImmuneN/AN/AN/AN/AN/AALTAltimmuneN/AN/AN/AN/AN/ACNTBConnect BiopharmaN/AN/AN/AN/AN/AIMABI-MabN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioACIUAC ImmuneN/A1.331.33ALTAltimmune0.0920.4420.44CNTBConnect Biopharma0.017.247.24IMABI-MabN/A22.8222.82Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipACIUAC Immune51.36%ALTAltimmune78.05%CNTBConnect Biopharma58.72%IMABI-Mab38.38%Insider OwnershipCompanyInsider OwnershipACIUAC Immune4.60%ALTAltimmune4.40%CNTBConnect Biopharma22.60%IMABI-Mab22.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableACIUAC Immune140100.41 million95.79 millionOptionableALTAltimmune5088.26 million84.37 millionOptionableCNTBConnect Biopharma11055.72 million43.13 millionOptionableIMABI-Mab38081.66 million63.61 millionOptionableCNTB, ACIU, IMAB, and ALT HeadlinesRecent News About These CompaniesWhat Makes IMab (IMAB) a New Buy StockOctober 6 at 1:01 PM | zacks.comI-Mab (NASDAQ:IMAB) Upgraded to "Buy" at Wall Street ZenOctober 6 at 2:43 AM | americanbankingnews.comI-Mab (NASDAQ:IMAB) Upgraded at Leerink PartnrsOctober 6 at 2:07 AM | americanbankingnews.comLeerink Partners Initiates Coverage of I-Mab - Depositary Receipt (IMAB) with Outperform RecommendationOctober 4 at 12:46 PM | msn.comI-Mab (NASDAQ:IMAB) Upgraded to Strong-Buy at Leerink PartnrsOctober 4 at 6:01 AM | marketbeat.comI-Mab (NASDAQ:IMAB) Upgraded to Buy at Wall Street ZenOctober 3, 2025 | marketbeat.comI-Mab initiated with an Outperform at LeerinkOctober 3, 2025 | msn.comI-Mab Sponsored ADR (NASDAQ:IMAB) Given Average Rating of "Buy" by AnalystsOctober 3, 2025 | marketbeat.comI-Mab to Vote on Name Change to NovaBridge BiosciencesSeptember 25, 2025 | msn.comI-Mab (IMAB) Shows 83% Response Rate for Givastomig in Metastatic Gastric CancerSeptember 23, 2025 | msn.comI-Mab (NASDAQ:IMAB) Rating Lowered to "Hold" at Wall Street ZenSeptember 20, 2025 | marketbeat.comI-Mab (NASDAQ:IMAB) Earns Buy Rating from Analysts at BTIG ResearchSeptember 11, 2025 | marketbeat.comI-Mab: Sudden Pivot To Gastric Cancer Med Still Underappreciated By MarketSeptember 10, 2025 | seekingalpha.comNeedham & Company LLC Reaffirms Buy Rating for I-Mab (NASDAQ:IMAB)September 10, 2025 | marketbeat.comBTIG Initiates Coverage of I-Mab - Depositary Receipt () (IMAB) with Buy RecommendationSeptember 9, 2025 | msn.comI-Mab initiated with a Buy at BTIGSeptember 9, 2025 | msn.comI-Mab Announces Leadership Changes and Accelerated Investment in GivastomigSeptember 9, 2025 | msn.comI-Mab announces accelerated investment in givastomig programSeptember 9, 2025 | msn.comI-Mab Announces Acceleration of Givastomig Investment and Leadership AppointmentsSeptember 9, 2025 | markets.businessinsider.comI-Mab to accelerate investment in givastomigSeptember 9, 2025 | msn.comI-Mab Insiders Land Bargain With Gains Of US$5.0mAugust 31, 2025 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCNTB, ACIU, IMAB, and ALT Company DescriptionsAC Immune NASDAQ:ACIU$3.59 +0.05 (+1.41%) Closing price 04:00 PM EasternExtended Trading$3.54 -0.05 (-1.39%) As of 07:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.Altimmune NASDAQ:ALT$3.93 -0.08 (-2.00%) Closing price 04:00 PM EasternExtended Trading$3.92 -0.01 (-0.15%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.Connect Biopharma NASDAQ:CNTB$1.78 +0.18 (+11.25%) Closing price 04:00 PM EasternExtended Trading$1.84 +0.06 (+3.65%) As of 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.I-Mab NASDAQ:IMAB$4.37 +0.02 (+0.46%) Closing price 04:00 PM EasternExtended Trading$4.36 -0.01 (-0.34%) As of 06:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics in the fields of immuno-oncology and immuno-inflammation diseases primarily in the United States. It is developing Uliledlimab, a CD73 neutralizing antibody, which is in Phase 2 clinical trial for the treatment of solid tumors; Givastomig, a bi-specific antibody that is in Phase 1 clinical trial for the treatment of gastric and other cancers; and Ragistomig, a programmed cell death ligand-based tumor-dependent T cell engager, which is in Phase 1 clinical trial for the treatment of for solid tumors. The company is also evaluating opportunities to develop Lemzoparlimab, a fully human CD47 monoclonal antibody for cancer immunotherapy. It has strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell and offer to sell FE301, an interleukin-6 inhibitor. The company has clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific antibody givastomig in combination with nivolumab and chemotherapy for the treatment of gastric and esophageal cancer. I-Mab was founded in 2014 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End The Juice Is Loose: Why Plug Power's Rally Is Just the Beginning Joby's Stock Rallies as Public Flights Validate Global Game Plan SharkNinja Is Flashing a Buy Signal the Market Is Ignoring Why Semtech Stock Is Rallying After Its NVIDIA Setback Marvell Insiders Buy Shares—Should Investors Follow Suit? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
